Idiopathic pulmonary fibrosis is strongly associated with productive infection by herpesvirus saimiri. Folcik VA, Garofalo M, Coleman J, Donegan JJ, Rabbani E, Suster S, Nuovo A, Magro CM, Di Leva G, Nuovo GJ. Mod Pathol. 2014 Jun;27(6):851-62. doi:10.1038/modpathol.2013.198 . PMID: #24232864# [Free]
humpath.com supports the 2014 edition of the European Symposium of Biopathology, June 19th and 20th 2014 in Paris, France.
Macroscopy, Microscopy, Videos, Digital slides, Virtual slides, Digital pathology, Biopathology, Molecular Pathology
Most recent articles
The proposed IASLC/ATS/ERS classification of lung adenocarcinoma identifies histological categories with prognostic differences that may be helpful in identifying candidates for adjunctive therapy. (#21252858#)
In a study (#21252858#), three overall prognostic groups were identified:
low grade: adenocarcinoma in situ (n=1) and minimally invasive adenocarcinoma (n=8) had 100% 5-year disease-free survival;
intermediate grade: non-mucinous lepidic predominant (n=29), papillary (...)
The ossifying renal tumor of infancy is a rare neoplasm diagnosed in the first 2 years of life, predominantly in boys. The neoplasm is primarily characterized by the presence of a large ossifying component. Its most common mode of presentation is hematuria, and it has a uniformly benign behavior.
clonal trisomy 4
Clonal trisomy 4 cells detected in the ossifying renal tumor of infancy: study of 3 cases. Liu J, Guzman MA, Pawel BR, Pezanowski DM, Patel DM, (...)
Olaparib is an inhibitor (PARP inhibitor) of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair.
Olaparib (AZD-2281) is an experimental chemotherapeutic agent, developed by KuDOS Pharmaceuticals and later by AstraZeneca, that is currently undergoing clinical trials.
It is an inhibitor of poly ADP ribose polymerase (PARP), an enzyme involved in DNA repair. It acts against cancers in people with hereditary BRCA1 or BRCA2 mutations, which includes many ovarian, breast (...)
Ibrutinib is an inhibitor of the enzyme Bruton’s tyrosine kinase (BTK).
Ibrutinib (USAN, also known as PCI-32765 and marketed in the U.S. under the name Imbruvica) is an anticancer drug targeting B-cell malignancies. It was approved by the US FDA in November 2013 for the treatment of mantle cell lymphoma and in February 2014 for the treatment of chronic lymphocytic leukemia.
It is an orally-administered, selective and covalent inhibitor of the enzyme Bruton’s tyrosine kinase (BTK). (...)
Alectinib (Chugai, NDA has been filed in Japan) is an ALK inhibitor (WP).
Nivolumab, a drug in clinical trials also known as BMS-936558 or MDX1106, is a fully human IgG4 monoclonal antibody developed by Bristol-Myers Squibb for the treatment of cancer.
Nivolumab acts as an immunomodulator by blocking ligand activation of the programmed cell death 1 (PD-1) receptor on activated T cells.
Enzalutamide (marketed as Xtandi and formerly known as MDV3100) is an androgen receptor antagonist drug developed by the pharmaceutical company Medivation for the treatment of metastatic castration-resistant prostate cancer.
Medivation has reported up to an 89% decrease in prostate specific antigen serum levels after a month of taking the medicine.
Early preclinical studies also suggest that enzalutamide inhibits breast cancer cell growth.
In August 2012, the U.S. Food and Drug (...)
previous page | next page